

# Contents

---

<b>Historical Overview</b> . . . . .	1
<b>1 Tumor Angiogenesis: from Bench to Bedside</b> JUDAH FOLKMAN. . . . .	3
<b>Mechanisms</b> . . . . .	29
<b>2 Vasculogenesis and Angiogenesis in Development</b> ANNE EICHMANN, KARINE BOUVRÉE, and LUC PARDANAUD . . . . .	31
<b>3 Guidance of Vascular and Neuronal Network Formation</b> CARMEN RUIZ DE ALMODOVAR, SERENA ZACCHIGNA, MONICA AUTIERO, and PETER CARMELIET . . . . .	47
<b>4 The Angiogenic Switch in Tumorigenesis</b> ANDREAS WICKI and GERHARD CHRISTOFORI . . . . .	67
<b>5 Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor</b> NAPOLEONE FERRARA. . . . .	89
<b>6 Regulation of Angiogenesis and Vascular Homeostasis Through the Angiopoietin/Tie System</b> HELLMUT G. AUGUSTIN and ULRIKE FIEDLER . . . . .	109
<b>7 Eph Receptors and Ephrins: Role in Vascular Development and Tumor Angiogenesis</b> DANA M. BRANTLEY-SIEDERS and JIN CHEN. . . . .	121
<b>8 The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression</b> GERA NEUFELD and OFRA KESSLER. . . . .	135

---

<b>9 Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis</b>	
ARNE ÖSTMAN and CHRISTER BETSHOLTZ . . . . .	155
<b>10 Hypoxia and Tumour Angiogenesis</b>	
M. CHRISTIANE BRAHIMI-HORN, JULIE LAFERRIÈRE, NATHALIE MAZURE, and JACQUES POUYSSEGUR . . . . .	171
<b>11 Hypoxia and Angiogenesis in Glioblastomas</b>	
TILL ACKER and KARL H. PLATE . . . . .	195
<b>12 Endogenous Inhibitors of Angiogenesis</b>	
MALIN SUND and RAGHU KALLURI . . . . .	215
<b>13 Thrombospondins and Angiogenesis</b>	
NATHAN V. LEE and M. LUISA IRUELA-ARISPE . . . . .	233
<b>14 Molecular and Cellular Aspects of Heparanase</b>	
NETA ILAN, LIAT FUX, MICHAEL ELKIN, and ISRAEL VLODAVSKY . . . . .	247
<b>15 Vessel Maturation and Perivascular Cells</b>	
ANNE M. GOODWIN and PATRICIA A. D'AMORE . . . . .	273
<b>16 Adhesion Molecules in the Vascular Cell Cross-Talk</b>	
UGO CAVALLARO . . . . .	289
<b>17 Homing and Differentiation of Endothelial Progenitor Cells</b>	
CARMEN URBICH, EMMANOUIL CHAVAKIS, and STEFANIE DIMMELER. . . . .	309
<b>18 Molecular Players in Lymphangiogenesis</b>	
MARJA LOHELA and KARI ALITALO . . . . .	325
<b>19 The Relationship Between Tumors and the Lymphatics: Consequences for Metastasis</b>	
JONATHAN P. SLEEMAN . . . . .	341
<b>20 Inflammation and Angiogenesis: Innate Immune Cells as Modulator of Tumor Vascularization</b>	
MARGARETA M. MUELLER . . . . .	351
<b>21 Arteriovenous Malformation in Mice and Men</b>	
NICOLE REVCNU, LAURENCE BOON, MIKKKA VIKKULA . . . . .	363

---

---

<b>Animal Models and Preclinical Anti-Angiogenic Studies. . . . .</b>	<b>375</b>
<b>22 Vascular Endothelial Growth Factor Antibodies for Anti-angiogenic Therapy</b>	
HANS-PETER GERBER, MEGAN E. BALDWIN, and FARBOD SHOJAEI. . . . .	377
<b>23 Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer</b>	
STEPHEN R. WEDGE and JULIANE M. JÜRGENSMEIER. . . . .	395
<b>24 Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy</b>	
PETER BOHLEN, ZHENPING ZHU, and DANIEL J. HICKLIN. . . . .	425
<b>25 Angiopoietin-2 Antagonists for Anti-Angiogenic Therapy</b>	
PAUL E. HUGHES, ANTHONY POLVERINO, JONATHAN D. OLINER, and RICHARD L. KENDALL. . . . .	453
<b>26 Anti-Angiogenic Therapy with Thrombospondins</b>	
JACK LAWLER. . . . .	465
<b>27 The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer</b>	
ROBERT R. LANGLEY, SUN-JIN KIM, and ISAIAH J. FIDLER. . . . .	477
<b>28 Vascular Tumor Targeting</b>	
DRAGAN GRABULOVSKI and DARIO NERI. . . . .	491
<b>29 Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis</b>	
JAMES P. B. O'CONNOR, DANIELA D. ROSA, ALAN JACKSON, and GORDON C. JAYSON. . . . .	511
<b>30 Imaging of Tumor Angiogenesis and Antiangiogenesis</b>	
FABIAN KIESSLING and MARTIN KRIX. . . . .	529
<b>31 Visualization of Microcirculation and Anti-Angiogenic Tumor Therapy</b>	
MARCUS CZABANKA and PETER VAJKOCZY. . . . .	545
<b>32 Cellular Actions of Angiogenesis Inhibitors on Blood Vessels</b>	
PETER BALUK, BEVERLY L. FALCÓN, HIROYA HASHIZUME, BARBARA SENNINO, and DONALD M. McDONALD. . . . .	557
<b>33 Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment</b>	
RAKESH K. JAIN and DAN G. DUDA. . . . .	577

---

<b>34 Metronomic Antiangiogenic Chemotherapy: Questions and Answers</b>	
ROBERT S. KERBEL, URBAN EMMENEGGER, SHAN MAN, RAQUEL MUNOZ, FRANCESCO BERTOLINI, and YUVAL SHAKED . . . . .	593
 <b>Anti-Angiogenic Tumor Therapy in Clinical Studies . . . . .</b>	 609
<b>35 The Development of Avastin</b>	
ROBERT MASS . . . . .	611
<b>36 Clinical Development of Sorafenib (BAY 43-9006), a VEGFR and RAF Inhibitor</b>	
DIMITRIS VOLIOTIS and J. DUMAS. . . . .	655
<b>37 Clinical Development of the VEGFR Signalling Inhibitor AZD2171</b>	
JOACHIM DREVS and CLEMENS UNGER . . . . .	673
<b>38 Clinical Development of Sunitinib Malate</b>	
ISAN CHEN, CARLO BELLO, and ZULEIMA AGUILAR . . . . .	689
<b>39 The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy</b>	
KLAAS HOEKMAN, HESTER VAN CRUIJSEN, and GUISEPPE GIACCONE . . . . .	707
<b>40 Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies</b>	
BRUNO MORGAN and MARK A. HORSFIELD . . . . .	717
<b>41 Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development</b>	
ALAN BARGE and ANDERSON J. RYAN. . . . .	741
<b>42 Integrins: Targets for Anti-Angiogenic Therapy</b>	
OLIVER KISKER . . . . .	761
<b>43 Thalidomide in Multiple Myeloma</b>	
THOMAS M. MOEHLER, JENS HILLENGASS, AXEL GLASMACHER, HARTMUT GOLDSCHMIDT . . . . .	779
<b>44 Surrogate Markers of Angiogenesis</b>	
VALENTINA RAIA, PATRIZIA MANCUSO, and FRANCESCO BERTOLINI . . . . .	795
<b>45 Vascular Disrupting Agents in Cancer Therapy</b>	
GILLIAN M. TOZER, CHRYSO KANTHOU, and DAVID J. CHAPLIN . . . . .	809
<b>Subject Index. . . . .</b>	<b>831</b>

---



<http://www.springer.com/978-3-540-33177-3>

Tumor Angiogenesis

Basic Mechanisms and Cancer Therapy

Marmé, D.; Fusenig, N. (Eds.)

2008, XVIII, 845 p.,

ISBN: 978-3-540-33177-3